Evidence map›Paper›PMID 39702074›Full record

ArticleBMC cardiovascular disorders2024

Cardiovascular disease burden in the North Africa and Middle East region: an analysis of the global burden of disease study 1990-2021.

Hamidreza Soleimani, Ali Nasrollahizadeh, Amir Nasrollahizadeh, Iman Razeghian, Mohammad Mahdi Molaei, Diaa Hakim, Khurram Nasir, Sadeer Al-Kindi, Kaveh Hosseini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Delivering Multidisciplinary Cardiac Care in Conflict Zones: A Cardiology Mission to Homs, Syria.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hamidreza SoleimaniCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran.
Ali NasrollahizadehCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran. ali.nasrollahi75@gmail.com.
Amir NasrollahizadehCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran.
Iman RazeghianSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Mahdi MolaeiSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Diaa HakimBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Khurram NasirDepartment of Cardiovascular Medicine, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Sadeer Al-KindiDepartment of Cardiovascular Medicine, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Kaveh HosseiniCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCardiovascular diseases (CVD) are a leading cause of mortality and morbidity in the North Africa and Middle East (NAME) region. Due to the paucity of research on this issue, we aimed to estimate the burden of CVD and its attributable risk factors in the NAME region. METHODS AND

resultsData from the Global Burden of Disease (GBD) were retrieved to estimate the incidence, prevalence, deaths, years of life lost, years lived with disability, disability-adjusted life years (DALYs) for CVD across 21 countries and both sexes. From 1990 to 2021, the incidence of CVD increased, but the age-standardized incidence rate slightly declined. The prevalence of CVD rose, with stable age-standardized prevalence rates. Additionally, the age-standardized DALY rate decreased from 11421.8 to 7353.8 per 100,000 people. Men consistently had higher rates of incidence, prevalence, deaths, and DALYs compared to women. Ischemic heart disease, stroke, and hypertensive heart disease were the leading causes of DALYs. Furthermore, high systolic blood pressure, dietary risks, and high LDL cholesterol were the top risk factors across NAME countries. countries with a history of war or ongoing conflict experience higher rates of death, disease burden (DALYs), and disease incidence compared to countries without such a history.

conclusionDespite the Progress in reducing the CVD burden in the NAME region, CVD remains a major public health problem, specifically due to significant sex disparities and various socio-economic factors. The study highlights the need for targeted interventions addressing these disparities and socio-economic determinants. CLINICAL TRIAL NUMBER: not applicable.

Indexed as

Cardiovascular DiseasesGlobal Burden of DiseaseAdultAfrica, NorthernAgedAged, 80 and overAge DistributionCause of DeathDisability-Adjusted Life YearsFemaleHumansIncidenceMaleMiddle AgedMiddle EastPrevalenceBurdenCardiovascular diseasesEpidemiologyNAMENorth Africa and Middle East

Identifiers

PMID39702074
PMCPMC11657751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.